BIOPOR.CO
$0.959
$
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.
Next Earnings
2026-02-25
Beta
1.251
Average Volume
Market Cap
Last Dividend
CIK
ISIN
DK0011048619
CUSIP
CEO
Carsten Buhl
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full Time Employees
48
IPO Date
2000-01-13
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering | 5. februar 2026Meddelelse nr. 1 BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering KØBENHAVN, DANMARK, 5. februar, 2026, (GLOBE NEWSWIRE) - BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH: BIOPOR), annoncerede i dag foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering. | Globe News Wire | 2026-02-05 15:01:13 |
Algorithm Performance
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|